Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Efficacy of 2.5-mg Prasugrel in Elderly or Low-Body-Weight Patients.

Wakabayashi S, Ariyoshi N, Kitahara H, Fujii K, Fujimoto Y, Kobayashi Y.

Circ J. 2018 Jun 29. doi: 10.1253/circj.CJ-18-0337. [Epub ahead of print]

2.

An extremely high bioavailability of orally administered vancomycin in a patient with severe colitis and renal insufficiency.

Yamazaki S, Suzuki T, Suzuki T, Takatsuka H, Ishikawa M, Hattori N, Fujishiro T, Miyauchi H, Oami T, Ariyoshi N, Oda S, Matsubara H, Ishii I.

J Infect Chemother. 2017 Dec;23(12):848-851. doi: 10.1016/j.jiac.2017.08.004. Epub 2017 Oct 12.

PMID:
28923303
3.

Wanted and Unwanted Care: The Double-Edged Sword of Partial Do-Not-Resuscitate Orders.

Ariyoshi N, Nogi M, Sakai D, Hiraoka E, Fischberg D.

J Palliat Med. 2018 Feb;21(2):143-148. doi: 10.1089/jpm.2017.0144. Epub 2017 Jul 31.

PMID:
28759312
4.

Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome.

Wakabayashi S, Kitahara H, Nishi T, Sugimoto K, Nakayama T, Fujimoto Y, Ariyoshi N, Kobayashi Y.

Cardiovasc Interv Ther. 2018 Jul;33(3):239-246. doi: 10.1007/s12928-017-0475-8. Epub 2017 Jun 12.

PMID:
28608310
5.

Cardiovascular consequences of hypophosphatemia.

Ariyoshi N, Nogi M, Ando A, Watanabe H, Umekawa S.

Panminerva Med. 2017 Sep;59(3):230-240. doi: 10.23736/S0031-0808.17.03331-6. Epub 2017 May 12.

PMID:
28497938
6.

Hypophosphatemia-induced Cardiomyopathy.

Ariyoshi N, Nogi M, Ando A, Watanabe H, Umekawa S.

Am J Med Sci. 2016 Sep;352(3):317-23. doi: 10.1016/j.amjms.2016.04.013. Epub 2016 Apr 22. Review.

PMID:
27650239
7.

Impact of chronic kidney disease on platelet inhibition of clopidogrel and prasugrel in Japanese patients.

Nishi T, Ariyoshi N, Nakayama T, Fujimoto Y, Sugimoto K, Wakabayashi S, Hanaoka H, Kobayashi Y.

J Cardiol. 2017 May;69(5):752-755. doi: 10.1016/j.jjcc.2016.07.017. Epub 2016 Aug 24.

8.

Streptococcus agalactiae mural infective endocarditis in a structurally normal heart.

Ariyoshi N, Miyamoto K, Bolger DT.

J Community Hosp Intern Med Perspect. 2016 Apr 25;6(2):31113. doi: 10.3402/jchimp.v6.31113. eCollection 2016.

9.

[A case of Marchiafava-Bignami disease suggesting vasogenic edema].

Nakamura Y, Matsuya M, Ikeda K, Tsuda R, Ariyoshi N, Shimohama S.

Rinsho Shinkeigaku. 2016;56(1):17-22. doi: 10.5692/clinicalneurol.cn-000774. Epub 2015 Nov 30. Japanese.

PMID:
26616486
10.

Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease.

Nishi T, Ariyoshi N, Nakayama T, Fujimoto Y, Sugimoto K, Takahara M, Wakabayashi S, Koshizaka M, Hanaoka H, Kobayashi Y.

Circ J. 2015;79(11):2439-44. doi: 10.1253/circj.CJ-15-0546. Epub 2015 Aug 27.

11.

Organic anion transporting polypeptide 2B1 expression correlates with uptake of estrone-3-sulfate and cell proliferation in estrogen receptor-positive breast cancer cells.

Matsumoto J, Ariyoshi N, Sakakibara M, Nakanishi T, Okubo Y, Shiina N, Fujisaki K, Nagashima T, Nakatani Y, Tamai I, Yamada H, Takeda H, Ishii I.

Drug Metab Pharmacokinet. 2015 Apr;30(2):133-41. doi: 10.1016/j.dmpk.2014.10.005. Epub 2014 Nov 14.

PMID:
25857231
12.

Genetic and non-genetic factors responsible for antiplatelet effects of clopidogrel in Japanese patients undergoing coronary stent implantation: an algorithm to predict on-clopidogrel platelet reactivity.

Miura G, Ariyoshi N, Sato Y, Yamaguchi H, Iwata Y, Fujimoto Y, Kobayashi Y, Ishii I.

Thromb Res. 2014 Oct;134(4):877-83. doi: 10.1016/j.thromres.2014.07.018. Epub 2014 Aug 14.

PMID:
25175362
13.

Yellow nail syndrome.

Ariyoshi N, Nakamura A, Kashima M.

Intern Med. 2013;52(24):2833. No abstract available.

14.

Functional characterization of seven single-nucleotide polymorphisms of the steroid sulfatase gene found in a Japanese population.

Matsumoto J, Ariyoshi N, Ishii I, Kitada M.

J Hum Genet. 2013 May;58(5):267-72. doi: 10.1038/jhg.2013.12. Epub 2013 Mar 7.

PMID:
23466819
15.

Development of a simple method for detection of the HLA-A*31:01 allele.

Uchiyama K, Kubota F, Ariyoshi N, Matsumoto J, Ishii I, Kitada M.

Drug Metab Pharmacokinet. 2013;28(5):435-8. Epub 2013 Feb 12.

16.

[Drug therapy and pharmacogenetics].

Ariyoshi N.

Arerugi. 2012 Jul;61(7):941-7. Review. Japanese. No abstract available.

PMID:
23007331
17.

Correlation between antizyme 1 and differentiation of vascular smooth muscle cells cultured in honeycomb-like type-I collagen matrix.

Ishii I, Suzuki T, Kaneko H, Uchida M, Suzuki Y, Higashi K, Yagi S, Ariyoshi N, Igarashi K, Kitada M.

Amino Acids. 2012 Feb;42(2-3):565-75. doi: 10.1007/s00726-011-1034-8. Epub 2011 Sep 6.

PMID:
21894530
18.

Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262.

Ariyoshi N, Ohara M, Kaneko M, Afuso S, Kumamoto T, Nakamura H, Ishii I, Ishikawa T, Kitada M.

Drug Metab Dispos. 2011 Nov;39(11):2045-8. doi: 10.1124/dmd.111.039586. Epub 2011 Aug 5.

19.

Degradation of filamin induces contraction of vascular smooth muscle cells in type-I collagen matrix honeycombs.

Uchida M, Ishii I, Hirata K, Yamamoto F, Tashiro K, Suzuki T, Nakayama Y, Ariyoshi N, Kitada M.

Cell Physiol Biochem. 2011;27(6):669-80. doi: 10.1159/000330076. Epub 2011 Jun 17.

20.

Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.

Noguchi A, Kaneko T, Kamigaki T, Fujimoto K, Ozawa M, Saito M, Ariyoshi N, Goto S.

Cytotherapy. 2011 Jan;13(1):92-7. doi: 10.3109/14653249.2010.515581. Epub 2010 Sep 10.

PMID:
20831354
21.

Six novel single nucleotide polymorphisms of the steroid sulfatase gene in a Japanese population.

Matsumoto J, Ariyoshi N, Ishii I, Kitada M.

Drug Metab Pharmacokinet. 2010;25(4):403-7.

22.

Enhanced susceptibility of HLA-mediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese.

Ariyoshi N, Iga Y, Hirata K, Sato Y, Miura G, Ishii I, Nagamori S, Kitada M.

Drug Metab Pharmacokinet. 2010;25(3):298-306.

23.

Application of Akaike information criterion to evaluate warfarin dosing algorithm.

Harada T, Ariyoshi N, Shimura H, Sato Y, Yokoyama I, Takahashi K, Yamagata S, Imamaki M, Kobayashi Y, Ishii I, Miyazaki M, Kitada M.

Thromb Res. 2010 Sep;126(3):183-90. doi: 10.1016/j.thromres.2010.05.016. Epub 2010 Jun 9.

PMID:
20553802
24.

Kefiran reduces atherosclerosis in rabbits fed a high cholesterol diet.

Uchida M, Ishii I, Inoue C, Akisato Y, Watanabe K, Hosoyama S, Toida T, Ariyoshi N, Kitada M.

J Atheroscler Thromb. 2010 Sep 30;17(9):980-8. Epub 2010 Jun 11.

25.

Super-acute onset of tumor lysis syndrome accompanied by hypercytokinemia during treatment of Hodgkin's lymphoma with ABVD chemotherapy.

Suzuki T, Takeuchi M, Saeki H, Yamazaki S, Koga H, Abe D, Nishimura M, Nakaseko C, Nakasa H, Nakamura H, Ariyoshi N, Kitada M.

Clin Ther. 2010 Mar;32(3):527-31. doi: 10.1016/j.clinthera.2010.03.010.

PMID:
20399989
26.

Unexpected serum level of vancomycin after oral administration in a patient with severe colitis and renal insufficiency.

Yamazaki S, Nakamura H, Yamagata S, Miura G, Hattori N, Shinozaki K, Sadahiro T, Toyoda A, Nakasa H, Ariyoshi N, Oda S, Harigaya K, Kitada M.

Int J Clin Pharmacol Ther. 2009 Nov;47(11):701-6.

PMID:
19840535
27.

Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.

Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, Sato K, Hosoi A, Nakajima J, Yoshida Y, Shiraishi K, Nakagawa K, Kakimi K.

Cytotherapy. 2008;10(8):842-56. doi: 10.1080/14653240802419328.

PMID:
19016372
28.

Growth inhibition and differentiation of cultured smooth muscle cells depend on cellular crossbridges across the tubular lumen of type I collagen matrix honeycombs.

Suzuki T, Ishii I, Kotani A, Masuda M, Hirata K, Ueda M, Ogata T, Sakai T, Ariyoshi N, Kitada M.

Microvasc Res. 2009 Mar;77(2):143-9. doi: 10.1016/j.mvr.2008.08.006. Epub 2008 Sep 18.

PMID:
18848952
29.

Probable interaction between warfarin and antitumor agents used in R-ESHAP chemotherapy.

Suzuki T, Koga H, Yamazaki S, Saeki H, Tanaka H, Nishimura M, Nakaseko C, Nakasa H, Nakamura H, Ariyoshi N, Kitada M.

Clin Ther. 2008 Jun;30(6):1155-9. doi: 10.1016/j.clinthera.2008.06.008.

PMID:
18640471
30.

[Appropriate use of anti-methicillin-resistant Staphylococcus aureus agents in a retrospective study].

Nakamura Y, Yokoyama I, Hashimoto N, Hasegawa A, Nakasa H, Nakamura H, Watanabe M, Nomura F, Watanabe A, Igari H, Sato T, Nakazawa K, Ariyoshi N, Kitada M.

Yakugaku Zasshi. 2008 Jul;128(7):1073-9. Japanese.

31.

Population pharmacokinetics of oral busulfan in young Japanese children before hematopoietic stem cell transplantation.

Nakamura H, Sato T, Okada K, Miura G, Ariyoshi N, Nakazawa K, Kitada M.

Ther Drug Monit. 2008 Feb;30(1):75-83. doi: 10.1097/FTD.0b013e3181621cde.

PMID:
18223466
32.
33.

Identification and partial characterization of a novel CYP2C9 splicing variant encoding a protein lacking eight amino acid residues.

Ariyoshi N, Shimizu Y, Kobayashi Y, Nakamura H, Nakasa H, Nakazawa K, Ishii I, Kitada M.

Drug Metab Pharmacokinet. 2007 Jun;22(3):187-94.

34.

Theoretical calculation of triazolam hydroxylation and endogenous steroid inhibition in the active site of CYP3A4.

Torimoto N, Ishii I, Hata M, Kobayashi Y, Nakamura H, Ariyoshi N, Kitada M.

Biochim Biophys Acta. 2007 Feb;1774(2):223-32. Epub 2006 Nov 30.

PMID:
17204458
35.

Helices F-G are important for the substrate specificities of CYP3A7.

Torimoto N, Ishii I, Toyama K, Hata M, Tanaka K, Shimomura H, Nakamura H, Ariyoshi N, Ohmori S, Kitada M.

Drug Metab Dispos. 2007 Mar;35(3):484-92. Epub 2006 Dec 18.

36.

CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes.

Nakamura H, Ariyoshi N, Okada K, Nakasa H, Nakazawa K, Kitada M.

Curr Drug Metab. 2005 Oct;6(5):469-80.

PMID:
16248838
37.

Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes.

Nakamura K, Ariyoshi N, Iwatsubo T, Fukunaga Y, Higuchi S, Itoh K, Shimada N, Nagashima K, Yokoi T, Yamamoto K, Horiuchi R, Kamataki T.

Biol Pharm Bull. 2005 May;28(5):882-5.

38.
39.

Effects of continuous ingestion of green tea or grape seed extracts on the pharmacokinetics of midazolam.

Nishikawa M, Ariyoshi N, Kotani A, Ishii I, Nakamura H, Nakasa H, Ida M, Nakamura H, Kimura N, Kimura M, Hasegawa A, Kusu F, Ohmori S, Nakazawa K, Kitada M.

Drug Metab Pharmacokinet. 2004 Aug;19(4):280-9.

40.

[CT perfusion abnormalities in a case of non-herpetic acute limbic encephalitis].

Nonaka M, Ariyoshi N, Shonai T, Kashiwagi M, Imai T, Chiba S, Matsumoto H.

Rinsho Shinkeigaku. 2004 Aug;44(8):537-40. Japanese.

PMID:
15471090
41.

Topogenesis of NHE1: direct insertion of the membrane loop and sequestration of cryptic glycosylation and processing sites just after TM9.

Sato Y, Ariyoshi N, Mihara K, Sakaguchi M.

Biochem Biophys Res Commun. 2004 Nov 5;324(1):281-7.

PMID:
15465015
42.

Identification of deletion-junction site of CYP2A6*4B allele lacking entire coding region of CYP2A6 in Japanese.

Ariyoshi N, Sekine H, Nakayama K, Saito K, Miyamoto A, Kamataki T.

Pharmacogenetics. 2004 Oct;14(10):701-5. No abstract available.

PMID:
15454735
43.

The use of urine to clarify the genotype of a patient with toxic phenytoin concentrations who had undergone peripheral blood stem cell transplantation.

Ariyoshi N, Sho-no K, Nishimura M, Ito M, Nakamura H, Asai T, Saitoh Y, Ishizaki T, Kitada M.

Br J Clin Pharmacol. 2004 Aug;58(2):225-6. No abstract available.

44.

Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4.

Torimoto N, Ishii I, Hata M, Nakamura H, Imada H, Ariyoshi N, Ohmori S, Igarashi T, Kitada M.

Biochemistry. 2003 Dec 30;42(51):15068-77.

PMID:
14690416
45.

[The interchange between hospital pharmacists and pharmacists: evaluation of practical classes "chozaigijutsu-konwakai" from the participants].

Nakamura Y, Nakasa H, Hasegawa A, Matsushima T, Kimura M, Shibata M, Miura G, Inano Y, Ohtsuka T, Akashi R, Tanno K, Ariyoshi N, Nakazawa K, Nakamura H, Ohmori S, Kitada M.

Yakugaku Zasshi. 2003 Jun;123(6):463-8. Japanese.

46.

Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults.

Ando M, Hamajima N, Ariyoshi N, Kamataki T, Matsuo K, Ohno Y.

J Epidemiol. 2003 May;13(3):176-81.

47.

CYP3A4 and CYP3A7-mediated carbamazepine 10,11-epoxidation are activated by differential endogenous steroids.

Nakamura H, Torimoto N, Ishii I, Ariyoshi N, Nakasa H, Ohmori S, Kitada M.

Drug Metab Dispos. 2003 Apr;31(4):432-8.

48.

New allelic arrangement CYP2D6*36 x 2 found in a Japanese poor metabolizer of debrisoquine.

Chida M, Ariyoshi N, Yokoi T, Nemoto N, Inaba M, Kinoshita M, Kamataki T.

Pharmacogenetics. 2002 Nov;12(8):659-62. No abstract available.

PMID:
12439227
49.

[Clinical pharmacogenetics and future prospects in drug therapy].

Ariyoshi N.

Nihon Yakurigaku Zasshi. 2002 Sep;120(3):181-6. Review. Japanese.

PMID:
12271513
50.

Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.

Ariyoshi N, Miyamoto M, Umetsu Y, Kunitoh H, Dosaka-Akita H, Sawamura Y, Yokota J, Nemoto N, Sato K, Kamataki T.

Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):890-4.

Supplemental Content

Loading ...
Support Center